Recommendations for molecular assessments in AML include the following genes: FLT3 (both internal tandem duplications, ITD, and tyrosine kinase domain, TKD, mutations), IDH1 and IDH2 as therapeutic targets, and NPM1, CEBPA, DDX41, TP53, ASXL1, BCOR, EZH2, RUNX1, SF3B1, SRSF2, STAG2, U2AF1 and ZRSR2 as diagnostic/prognostic disease markers. This evidence concerns the gene DDX41 and acute myeloid leukemia.